Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis

Table 2

Subgroup analyses of the highest post-diagnostic aspirin exposure and prostate cancer-specific mortality risk.

Group	OR(95%CI)	Number of studies	I^2 (%)
Region
America	0.81(0.65,1.03)	9	48.1	0.052
Europe	1.12(0.88,1.41)	4	54.1	0.088
Study type
case-control	1.31(0.85,2.01)	1	NA	NA
cohort	0.89(0.74,1.07)	12	57.8	0.006
Participants
	0.91(0.74,1.11)	8	41.7	0.100
	0.92(0.65,1.28)	5	70.8	0.008
Age
	0.51(0.32,0.80)	4	0	0.417
	0.98(0.79,1.21)	5	67	0.017
Follow-up time
	0.89(0.76,1.05)	4	0	0.392
	0.96(0.74,1.24)	7	60.5	0.019
Quality
moderate	0.55(0.29,1.05)	4	66.4	0.030
high	1.01(0.84,1.21)	9	49.5	0.045
Adjusted for smoking
yes	0.96(0.71,1.31)	5	70.3	0.009
no	0.97(0.79,1.18)	7	31.3	0.189
Adjusted for cardiovascular events
yes	0.96(0.72,1.27)	6	64.6	0.015
no	0.96(0.78,1.19)	6	37.4	0.157

A total score of 4-6 was considered moderate quality, and 7-9 was deemed high quality.